Racura Oncology (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Racura Oncology Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Racura Oncology (ASX: RAC)
Latest News
Healthcare Shares
This ASX All Ords biotech share is on a 16% tear today
Healthcare Shares
Guess which ASX All Ords share is soaring 12% on a 'key step'
Healthcare Shares
2 ASX healthcare shares racing higher on positive updates
Share Gainers
Why Allkem, IGO, Northern Star, and Race Oncology shares are racing higher
Share Gainers
Why Aeris Resources, Evolution, Li-S Energy, and Race Oncology shares are charging higher
Share Gainers
4 ASX All Ords shares smashing the market on big news
Share Fallers
Why Block, Mincor, Race Oncology, and Weebit Nano shares are sinking today
Share Fallers
Why is ASX All Ords healthcare share Race Oncology plummeting 10% today?
Share Gainers
Why Neuren, Northern Star, Race Oncology, and Westgold shares are storming higher
Share Market News
4 ASX All Ords shares insiders have been buying up in January
Share Market News
This ASX All Ords director has bought 25,000 of his company's shares in a week
Share Gainers
Why Cogstate, Mayne Pharma, Race Oncology, and Whitehaven Coal are charging higher
Frequently Asked Questions
-
No, Racura Oncology does not pay dividends at this time.
-
Sydney-headquartered Racura Oncology listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.
Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.
